Ness Berming­ham looks to lead the wave of RNA edit­ing at new At­las up­start Ko­r­ro Bio

By the time Ness Berming­ham left In­tel­lia in late 2017, the gene-edit­ing biotech had se­cured its foot­ing as one of the pi­o­neers in the CRISPR/Cas9 space with a high­ly an­tic­i­pat­ed first-in-hu­man tri­al in the works. Re­turn­ing to his VC post at At­las Ven­ture, he sig­naled that he was look­ing to do it all over again with the next big start­up idea.

And now he’s ready to talk about that ven­ture, which rep­re­sents the lat­est evo­lu­tion of his long­stand­ing in­ter­est in tin­ker­ing with the genome — RNA edit­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER